Avid Bioservices Expanding Process-Development Capabilities
Avid Bioservices, a Tustin, California-based contract development and manufacturing organization (CDMO) of biopharmaceutical products derived from mammalian cell culture and a wholly owned subsidiary of Peregrine Pharmaceuticals, has provided an update on the company’s ongoing efforts to expand its process-development capabilities and laboratory space within its CDMO campus in Orange County, California.
Avid has begun those efforts, which include expanding its total available process-development laboratory space to more than 6,000 square feet, upgrading the infrastructure and equipment within its existing process-development laboratories, and implementing new technologies and equipment designed to facilitate high-throughput development of upstream and downstream manufacturing processes. The company is conducting this work in phases to avoid disruption to current customer programs, with the first new laboratories expected to be operational during the third quarter of 2018.
Avid says it is committed to supporting its new customer acquisition efforts. Recently, the company has signed new agreements with three additional undisclosed international drug-development companies, which are focused on Avid providing process-development and manufacturing services to support the advancement of each company’s biologic candidate into clinical development. The drug candidates involved in these agreements are being developed for application in certain cell-therapy, respiratory, and oncology indications. Avid has commenced work on each of these projects. The company has now executed master service agreements with four new clients in 2018 as compared with four similar agreements during the entire 2017 calendar year, according to Avid.
Source: Avid Bioservices